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CholesterolAdenosine receptors are a member of the large family of seven transmembrane spanning G protein coupled
receptors. The four adenosine receptor subtypes—A1, A2a, A2b, A3—exert their effects via the activation of one or
more heterotrimeric G proteins resulting in the modulation of intracellular signaling. Numerous studies over
the past decade have documented the complexity of G protein coupled receptor signaling at the level of
protein–protein interactions as well as through signaling cross talk. With respect to adenosine receptors, the
activation of one receptor subtype can have profounddirect effects in one cell type but little or no effect in other
cells. There is signiﬁcant evidence that the compartmentation of subcellular signaling plays a physiological role
in the ﬁdelity of G protein coupled receptor signaling. This compartmentation is evident at the level of the
plasma membrane in the form of membrane microdomains such as caveolae and lipid rafts. This review will
summarize and critically assess our current understanding of the role of membrane microdomains in
regulating adenosine receptor signaling. This article is part of a Special Issue entitled: “Adenosine Receptors”.osine Receptors”.
+1 313 577 8615.
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Adenosine, a purine nucleoside catabolite of ATP, exerts numerous
effects in mammalian organ systems. Adenosine can modulate cell
metabolism via several mechanisms, with the most direct being its
rephosphorylation to AMP via adenosine kinase to help restore/
maintain ATP levels. Adenosine, however, is best known for regulating
cell function via the activation of four distinct purinergic P1 adenosine
receptor (AR) subtypes—A1, A2a, A2b, A3—which are part of the large
family of seven transmembrane spanning G protein coupled receptors
(GPCR) [1,2]. The A1 and A2a subtypes are high-afﬁnity receptors,
whereas A2bAR and A3AR are low afﬁnity receptors. Thus, adenosine
can exert physiological effect under basal conditions as well asconditions of stress and inﬂammation when extracellular adenosine
levels increase.
Adenosine receptors couple to multiple G proteins and activate
various intracellular signaling pathways [3,4]. Many cell types express
multiple adenosine receptor subtypes, but in some cell types, activation
of these receptors exerts few effects, while in others, the same receptors
produce profound effects. For example, A1AR activation decreases cAMP
in adipocytes [5] and increases intracellular calcium in smooth muscle
cells [6,7], but in cardiac ventricular myocytes, A1AR appears to exert
little, if any, direct effects on these parameters [8,9]. Interestingly, in
cardiomyocytes, A1AR signiﬁcantly reduces these same parameters
during β1-adrenergic receptor stimulation resulting in the well known
A1AR anti-adrenergic effect [8,9]. There are also numerous reports that
adenosine receptors can heterodimerize to alter cell signaling [10–13].
These observations, as well as similar reports on other receptors,
indicate that GPCR signaling is very complex and multiple mechanisms
appear to be capable of controlling the ﬁdelity of signaling.
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One mechanism proposed for the regulation of subcellular
signaling is compartmentation at the level of cell membranes. These
membrane microdomains, more commonly referred to as lipid rafts,
are highly enriched in glycosylphosphatidylinositol (GPI)-anchored
proteins, sphingolipids, and cholesterol, imparting on them less
ﬂuidity as well as being relatively resistant to solubilization by non-
ionic detergents, such as Triton X-100, at cold temperatures [14–18].
A specialized type of lipid raft is characterized by the structural protein
caveolinwhich imparts a ﬂask-shaped invagination (50–100 nm) of the
membrane. These microdomains are referred to as caveolae. There are
three isoforms of caveolin, referred to as caveolin-1, -2, and -3, which
exhibit cell-speciﬁc expression patterns. For example, caveolin-1 is
highly expressed in endothelial cells but has little, if any, expression in
cardiac ventricularmyocytes,whereas the opposite expression proﬁle is
seen for caveolin-3 [15,19].
In addition to directly binding cholesterol, caveolin modulates
signal transduction by serving as a scaffold for numerous proteins,
some of which possess caveolin binding motifs [20–25]. Numerous
second messengers such as heterotrimeric G proteins, eNOS, extra-
cellular regulated mitogen activated protein kinase (ERK), PKC
isoforms, and adenylyl cyclase have been shown to be localized
and/or concentrated in caveolae and lipid rafts. There have also been
numerous reports that several GPCR are present in caveolae [25–28].
The co-localization of GPCR and second messengers in microdomains
may permit the rapid and selective activation or deactivation of
intracellular signaling as well as controlling its compartmentation.
Lipid rafts and caveolae can be isolated by various techniques. Due
to their high concentration of cholesterol and resistance to non-ionic
detergents, these membrane microdomains can be isolated by
differential centrifugation. The two most commonly cited methods
based on these principles are the techniques of Song et al. [20] and
Smart et al. [29]. The former method relies on membrane solubiliza-
tion with high pH (9.0) sodium carbonate; the resulting homogenate
is separated into multiple fractions (10–12) using discontinuous
sucrose gradient centrifugation. The method of Smart et al. [29]
utilizes Percoll gradient centrifugation followed by OptiPrep gradient
separation of caveolae membranes from bulk plasma membranes. A
supplemental approach for verifying the localization of proteins in
caveolae is to perform co-immunoprecipitation studies in caveolin-
enriched fractions.Fig. 1. Cardiomyocyte A1AR localization in caveolae membranes (CM). Panel A illustrates
that caveolin-3andeNOS inadult rat ventricularmyocytesare enriched inCMcompared to
bulk plasma membranes (PM). CM are devoid of transferrin receptors (TR) which are
located in intracellular membranes (IM) and clathrin. Panel B indicates that, in
unstimulated myocytes (buffer), the majority of A1AR immunoreactivity is in CM vs PM.
After stimulationwith theA1 agonist CCPA (200 nM, 15 min), A1AR immunoreactivitywas
only present in PM. Treatmentwith theA1AR antagonist DPCPX (200 nM)+CCPAblocked
the translocation of A1AR. PNS, postnuclear supernatant; CYTO, cytosol.
This researchwas originally published in the Journal of Biological Chemistry by Lasley et al.
Activated cardiac adenosine A1 receptors translocate out of caveolae. 2000; 275: 4417–
4421. ©The American Society for Biochemistry and Molecular Biology.3. Adenosine receptors and membrane microdomains
Over the past decade, signiﬁcant evidence has accumulated that
adenosine receptor signaling may be regulated via membrane
microdomains. Such regulation may include localization of adenosine
receptors in caveolae or lipid rafts, modulation of signaling, and
trafﬁcking. The initial evidence for this concept appears to be
observations by Andersson-Forsman and Gustafsson in 1985 that
ecto-5′-nucleotidase (CD73) in various types of guinea-pig smooth
muscle was localized in caveolae [30]. Several subsequent studies
have provided additional evidence for such a localization [31–33].
Ecto-5′-nucleotidase, a GPI-anchored protein, dephosphorylates
extracellular AMP to adenosine, and since adenosine is rapidly
catabolized to inosine, close proximity of extracellular adenosine to
adenosine receptors would provide optimal receptor activation. Such
a mechanism was proposed by Anderson in 1993 [14]. There are also
reports that concentrative nucleoside transporters-1 and -3 are
located in lipid rafts/caveolae [34,35]. Finally, it has been reported
that all four human adenosine receptor subtypes contain portions of
the caveolin binding motif [36]. This review will provide a critical
analysis of the evidence for adenosine receptor subtype localization in
membrane microdomains in various cell types.3.1. A1 adenosine receptors and membrane microdomains
The adenosine receptor subtype ﬁrst reported to be localized in lipid
rafts/caveolae, and for which the most evidence exists for such a
localization, is the A1 adenosine receptor (A1AR). Our laboratory
reported in 2000 that A1AR was concentrated in caveolae of adult rat
ventricular cardiomyocytes [37]. Using the caveolae isolationmethods of
Smart et al. [29], the caveolin-3 buoyant low-density fraction contained
b0.4% of the protein found in the initial postnuclear supernatant butwas
N7-fold enriched in cholesterol compared to the bulk plasmamembrane
(PM). As shown in Fig. 1A, the caveolaemembranes (CM)were enriched
in caveolin-3 andeNOSbutweredevoid of transferrin receptors (TR) and
clathrin. Fig. 1B illustrates that, under basal conditions (buffer), the
majority of the A1AR immunoreactivity (using a rabbit polyclonal
antibody raised against the third extracellular domain of the rat A1AR
receptor gene (amino acids 163–176)) was located in the caveolae
membranes. Cardiomyocytes were treated with adenosine deaminase
(ADA) to exclude possible stimulation of the A1 receptor by endogenous
adenosine.
Treatment of myocytes with the A1 agonist 2-chloro-N6-cyclo-
pentyladenosine (CCPA, 200 nM, 15 min) resulted in the loss of all
A1AR immunoreactivity from caveolin-3 enriched fractions to the bulk
plasma membrane fraction, an effect that was prevented by prior
treatment of the myocytes with the A1AR antagonist 8-cyclopentyl-
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immunoprecipitated with caveolin-3 in unstimulated cells but not
after agonist exposure. Using immunoﬂuorescence, we have observed
similar staining patterns for caveolin-3 (Fig. 2A) and A1AR (Fig. 2B) in
unstimulated rat cardiomyocytes (unpublished observations).
Our observations regarding A1AR concentration in caveolin-3
enriched fractions were subsequently reported by two other groups
[38,39]. Cavalli et al. [38], who solubilized rat myocardial membranes
with both the sodium carbonate method of Song et al. [20] and also
Triton X-100, observed that A1AR co-immunoprecipitated with
caveolin-3 and A1AR immunoﬂuorescence co-localized with caveo-
lin-3 immunoﬂuorescence in cardiomyocytes, similar to our observa-
tions in Fig. 2. Garg et al. [39] reported that A1AR could be co-
immunoprecipitated with caveolin-3 in adult rat ventricular cardio-
myocytes. Thus, using all two well-recognized techniques of isolating
caveolae and lipid rafts, as well as co-immunoprecipitation and
immunoﬂuorescence, myocardial A1AR appears to be concentrated in
caveolae under basal conditions.
Concurrent with our observations, Murthy and Makhlouf [40]
provided the initial evidence that A1AR stimulation could modulate
signaling in caveolae. These authors, using the sodium carbonate
method of Song et al. [20] to isolate caveolae in rabbit intestinal
smooth muscle cells, reported that Gαq/11, Gαi1/2, and Gαi3 were
present in caveolin-3 enriched fractions as well as heavier fractions.
The A1 agonist cyclopentyladenosine (CPA, 1 μM, 10 min) selectively
activated Gαi3 and resulted in a signiﬁcant increase in the amount of
Gαi3 (as well as Gβγ) that could be immunoprecipitated with
caveolin-3 in both whole cell lysates and caveolin-enriched fractions.
A1 agonist treatment in these cells was associated with increased PLC-
β activity, and pretreatment with CPA or acetylcholine signiﬁcantly
blunted the subsequent response to CPA. The authors concluded that
this blunted response was due to receptor desensitization as well as
binding of Gαi3 to caveolin-3. Interestingly, the authors observed that
CPA had no effect on phosphatidylinositol 4,5-bisphosphate (PIP2)
levels in Triton X-100 soluble fractions but decreased by 34% in Triton
X-100 insoluble fractions. Since caveolin is relatively resistant to
Triton solubilization, the authors concluded that PLC-β activity was
increased in caveolar fractions.
Despite the multiple observations that cardiac A1AR is localized in
caveolae membranes, the role that this speciﬁc localization plays in
cardiac A1AR signaling remains unclear. AdenosineA1 receptor activation
in normal cardiomyocytes exerts no direct effects on contractility,
intracellular calcium, or cAMP [8,9]. Thus, A1AR enrichment in
cardiomyocyte caveolae under basal conditions could provide highly
localized A1AR signaling in these cells. However, in only one of the above
studies was the localization of A1AR determined after agonist exposure.
We observed that A1AR immunoreactivity translocated from caveolar to
bulk plasma membranes, but not intracellular membranes, after A1
agonist exposure (15 min) [37]. This observation suggests that cardio-
myocyte A1AR does not rapidly internalize, but it is not clear what roleFig. 2. Immunoﬂuorescence evidence of co-localization of caveolin-3 (A) and A1AR (B
permeabilized, and incubated with either a mouse monoclonal antibody for caveolin-3 (A
secondary antibody.this change in localization plays in A1AR signaling. In normal myocar-
dium, A1AR stimulation exerts a potent inhibition of β1-adrenergic
contractile and biochemical responses (referred to as the A1 anti-
adrenergic effect). β-Adrenergic receptors, adenylyl cyclase, as well as
Gαs and Gαi, are localized, at least to some extent, in caveolae in adult
cardiomyocytes [41]. However, the β2-adrenergic receptor is localized in
caveolae to a much greater extent than β1-adrenergic receptors, which
are distributed more widespread in the plasma membrane. The
differential distributions of the β-adrenergic receptor subtypes in adult
cardiomyocytes are consistent with their different functional effects. The
activation of cardiac β2-adrenergic receptors is associated with little
increases in total intracellular calcium and cAMP levels and exerts only
small increases in contractility, whereas β1-adrenergic receptor stimu-
lation produces signiﬁcant increases in all of these parameters [42]. Our
observations indicate that the cardiomyocyte A1AR translocates out of
caveolae upon agonist exposure [37], but there have been no reports on
the localization of cardiacβ1-adrenergic receptors after agonist exposure.
Thus, the role of receptor localization in or movement out of membrane
microdomains in the cardiac A1AR anti-adrenergic effect remains
uncertain.
Although our observation that A1AR moves out of caveolae after
agonist exposure appears to be consistent with the A1AR anti-
adrenergic effect, there is additional evidence that cardiac A1AR may
modulate signaling in caveolaemembranes and/or detergent resistant
membranes. Garg et al. [39] reported that A1AR and the pore-forming
subunit of sarcolemmal KATP channels, Kir6.2, could be co-immuno-
precipitated with caveolin-3 in cardiomyocytes. These authors also
observed that the cholesterol reducing agent methyl-β-cyclodextrin
(MβCD) blunted A1AR agonist-mediated activation of KATP channels.
Interestingly, MβCD had no effect on the KATP channel activation by
the KATP channel opener pinacidil. We reported that A1AR agonist
treatment of adult rat cardiomyocytes decreased phosphorylation of
the mitogen activated protein kinases (MAPK) p38 and ERK in Triton
X-100 insoluble membranes but had no effect on these kinases in
Triton soluble membranes [43]. Most recently, Yang et al. [44]
reported that brief exposure of adult rat cardiomyocytes to an A1
agonist increased translocation of PKC-ε and PKC-δ into caveolin-3
enriched fractions. These observations suggest that, although A1AR
appears to translocate out of cardiomyocyte caveolae after agonist
stimulation, A1AR signaling still occurs in these microdomains.
Finally, there is evidence supporting an interaction between
caveolin-3 and A1AR in diseased myocardium. It has been reported
that cardiomyocyte-speciﬁc constitutive A1AR overexpression results
in hypertrophy and dilatation [45]. The results of a preliminary report
indicate that this cardiac pathology is associated with decreased
expression of caveolin-3 and altered localization of caveolin [46].
Interestingly, caveolin-3 KO mice also develop heart failure [47]. The
signiﬁcance of these interactions between A1AR expression and
caveolin-3 levels in the observed cardiac pathology remains to be
determined.) in adult rat ventricular myocytes. Myocytes were ﬁxed with paraformaldehyde,
) or rabbit polyclonal anti-A1AR (B) followed by the appropriate ﬂuorescently labeled
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modulate signaling in lipid rafts/caveolae. Ginés et al. [48] reported in
2001 that exposure of a porcine kidney epithelial cell line (LLC-PK1)
to the A1 agonist N6-(R)-phenylisopropyl-adenosine (PIA, 100 nM,
30 min) was associated with the translocation of A1 receptors from
high-density, caveolin-1 devoid fractions to lower density fractions,
including caveolin-1 enriched fractions. Fractions were isolated via
the detergent-free sodium carbonate method of Song et al. [20]. The
authors concluded that this was the mechanism by which A1
receptors were internalized in this cell type. Although the authors
did not test whether the LLC-PK1 A1AR could be co-immunoprecipi-
tated with caveolin-1, they did show that a GST-fusion protein,
containing the C-terminal domain of the A1 receptor, could interact
with caveolin-2. In addition, the authors stated that the C-terminal
cytoplasmic tail of the A1 receptor contains a sequence similar to the
caveolin binding domain. The primary question concerning these
observations is what role this redistribution into caveolin-1 enriched
fractions plays in A1AR-mediated effects on cAMP and inositol
phosphate production as well as solute transport in renal epithelial
cells. Thus, how these observations relate to epithelial cell function
remains unanswered.
The results of a subsequent study by this laboratory are consistent
with the hypothesis that A1AR in DDT1MF-2 cells internalize via
caveolae [49]. Using immunogold staining, it was observed that, under
control conditions, nearly all A1AR was in non-caveolin containing
membranes, but within 15 min exposure to 50 nM PIA, ~90% of
immunogold staining was present in caveolin containing membranes.
Continued exposure to PIA resulted in partial loss of caveolin co-
localization with A1AR increasing in intracellular vesicles, such that by
19 hours, all A1AR immunogold staining was in intracellular vesicles.
Treatment with ﬁlipin and MβCD, but not hyperosmolar sucrose or
acetic acid, blocked the internalization of A1AR. Filipin and MβCD
reduce membrane cholesterol levels which are concentrated in lipid
rafts and caveolae, whereas the latter two agents disrupt internali-
zation via clathrin-coated pits. These same investigators had previ-
ously reported that, in the DDT1MF-2 smooth muscle cell line, the
A1AR appeared to form clusters in speciﬁc locations in the plasma
membrane within 5 min after exposure to the A1 agonist PIA (50 nM)
[50]. These observations, in conjunction with the authors' previous
observations regarding A1AR trafﬁcking, indicate that initial move-
ment into caveolae plays a role in the internalization and desensiti-
zation in DDT1MF-2 smooth muscle cells. However, since there are
varying reports on the timescale of A1AR internalization and
desensitization [36,51], the role of caveolae in A1AR trafﬁcking may
be cell-speciﬁc.
The above information indicates that there is signiﬁcant evidence
for localization and/or translocation of A1AR into and out of caveolae
in muscle cells as well as epithelial cells. There is also evidence that
A1AR signaling may occur in caveolin-enrichedmembranes. However,
the speciﬁc role that these observations play in the physiological
effects of A1AR under normal conditions and in diseased tissue
remains to be elucidated.
3.2. A2a adenosine receptors and membrane microdomains
Adenosine A2a receptors (A2aAR) couple primarily to Gαs, although
there are some reports that A2aAR signal via Gαs-independent
mechanisms. One of the most recognized signaling effects of A2aAR
is the stimulation of adenylyl cyclase activity resulting in increased
intracellular cAMP levels. There are multiple reports in the literature
that both Gαs and adenylyl cyclase are present or are concentrated in
lipid rafts and/or caveolae in various cell types [18,25,26]. In contrast,
there are a very limited number of reports indicating the localization
of A2aAR in lipid rafts or caveolae. In fact, there appears to be only one
study to date providing evidence for A2aAR localization in these
membranemicrodomains. Mojsilovic-Petrovic et al. [52] reported thatA2aAR were present in lipid rafts in embryonic Sprague–Dawley rat
spinal cord neurons. This conclusion was based on the analysis of lipid
rafts generated using Triton X-100 and discontinuous sucrose
gradient centrifugation. Light fraction 2, which contained the lipid
raft marker Thy-1, contained some immunoreactivity for A2aAR based
on co-immunoprecipitation with anti-tyrosine kinase B receptor
(TrkB) using a mouse monoclonal anti-A2aAR. However, the complete
distribution of A2aAR in the 10 collected fractions was not shown, and
co-immunoprecipitation of the A2aAR with a lipid raft marker was not
shown. In addition, functional evidence of A2aAR localization in lipid
rafts was not provided. Given these limitations, it is not clear to what
extent A2aAR are actually localized in lipid rafts in these cells.
Assaife-Lopes et al. [53] provided some functional evidence for
A2aAR modulation of signaling in lipid rafts in cultured rat embryonic
cortical neurons. The A2aAR agonist CGS21680 (20 nM, 30 min)
increased the localization of TrkB in lipid rafts to a greater extent
than BDNF, an effect that was blocked by the A2aAR antagonist
ZM24135. This effect was not altered by the clathrin-dependent
endocytosis inhibitor monodansylcadaverine (MDC) but was blocked
after treatment of cells with the cholesterol reducing agent MβCD.
Although the authors did not determine whether A2aAR themselves
localized in lipid rafts or translocated into/out of lipid rafts after
activation, they did observe that MβCD treatment had no effect on
A2aAR density and Kd values.
The results of two additional studies suggest that disrupting lipid
rafts or reducingcholesterol itself can alterA2aAR signaling. Kamata et al.
[54] reported that a portion of Gαs in human erythrocyte membranes
was localized in detergent resistant lipid rafts, and this localization was
reversibly lost after brief lidocaine treatment. Lidocaine, which
disassembled lipid rafts in these membranes without reducing
cholesterol levels, reversibly blocked the effects of NECA on cAMP
accumulation and phosphorylation of adducin (a membrane protein).
Lam et al. [55] reported that cholesterol reductionwithMβCD inmouse
colon epithelial cells potentiated A2aAR activation of a basolateral K+
channel thus increasing the driving force for anion secretion. Interest-
ingly, neither ﬁlipin, which also decreasesmembrane cholesterol levels,
nor sphingomyelinase, which disrupts lipid rafts via degrading
sphingomyelin, mimicked the effects of MβCD. In addition, the
potentiating effects of A2aAR stimulation were absent in cells obtained
from caveolin-1 knockout mice. The authors concluded that membrane
cholesterol, but not the presence of lipid rafts or caveolae, modulated
the A2aAR effect on basolateral anion secretion. The contrasting
conclusions from these two studies raise questions concerning the
localization of A2aAR in membrane microdomains and/or suggest that
this may be cell-speciﬁc.
Thus, in contrast to the signiﬁcant evidence indicating that A1AR is
linked to caveolae and/or lipid rafts, the support for a similar
localization of the A2aAR is equivocal. The consistent ﬁnding with
respect to A2aAR, however, is that membrane cholesterol levels do
appear to modulate A2aAR signaling. Charalambous et al. [56] appear
to have an explanation for how this may occur. They provided
evidence in PC12 cells (rat pheochromocytoma cell line), embryonic
rat striatal neurons, and HEK cells (expressing tagged receptors) that
A2aAR stimulation with agonist or antagonist for time periods up to
1.5 hours did not internalize. Studies in HEK cells expressing yellow
ﬂuorescence protein (YFP)-tagged A2aAR utilizing ﬂuorescence
recovery after photobleaching (FRAP) indicated that the receptor
was restricted in lateral mobility independent of agonist or antagonist
binding, whereas A2aAR agonist stimulation did reducemobility of the
D2 dopamine/A2aAR hetero-oligomer. The authors determined that
this limited mobility of the A2aAR was due not to binding of the
C-terminus to cytoskeletal actin but rather to membrane cholesterol
levels (which were reduced by ﬁlipin and MβCD). Cholesterol
reduction did not alter A2aAR binding characteristics, as recently
reported by Assaife-Lopes et al. [53], but it did reduce the ability of the
receptor to couple to Gs and thus to increase cAMP levels, without
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phosphorylation. This elegant study, demonstrating the role of
cholesterol in regulation of A2aAR signaling, may help explain the
inconclusive observations regarding A2aAR and membrane micro-
domains. Consistent with these observations, Lyman et al. [57]
subsequently concluded that cholesterol stabilized helix II of the
apo conﬁguration of the human A2aAR.
3.3. A2bAR and A3AR and membrane microdomains
To date, there is one report supporting possible A2bAR localization in
lipid rafts or caveolae membrane microdomains, but there is no such
evidence for A3AR. Sitaraman et al. [58] studied A2bAR trafﬁcking in T84
epithelial cells and Caco2-BBE cells stably transfected with GFP-A2bAR.
Membraneswere isolated by themethods of Smart et al. [28]. In the T84
cell line under basal conditions, the majority of the A2bAR signal was
found in the postnuclear supernatant with very little signal in the
caveolar or plasma membrane fractions. After stimulation with
adenosine (100 μM, 5 min) there was a 2-fold increase in A2bAR in
caveolin-1 enriched fractions in both basolateral and apicalmembranes.
However, the signiﬁcance of this translocation was not addressed
further, and the vast majority of the A2bAR translocation (7–8 fold
increase) occurred to the bulk plasma membrane. Since co-immuno-
precipitation studies with caveolin-1 and A2bAR were not performed, it
is difﬁcult to determine whether A2bAR actually translocated to
caveolae. In contrast to these observations, it has been reported that
A2bAR in unstimulated transfected HEK293 cells were localized
primarily in the plasma membrane and rapidly (t1/2b4 min) internal-
ized, an effect that was blocked with arrestin antisense [59]. This early
internalization appeared to be occurring via endosomes. Although both
of these studies were conducted in cells transfected with A2bAR, these
differences support the notion that adenosine receptor trafﬁcking and
signaling appear to be cell type speciﬁc.
Although there is no evidence for A3AR localization in caveolae or
lipid rafts, there is a report that these receptors may be organized in
membrane microdomains. Cordeaux et al. [60] studied CHO cells
transfected with human A3AR. Using ﬂuorescence correlation spec-
troscopy (FCS), they observed that following exposure (2.5 nM,
10 min, 22°C) to a ﬂuorescent A3 agonist, ABEA-X-BY630, there
appeared to be two populations of agonist-occupied receptors based
on membrane diffusion coefﬁcients. They speculated that the
population with the slowest mobility could have been A3 receptor–
agonist complexes in caveolae or clathrin-coated pits. In fact, there is
evidence that A3AR may internalize via clathrin-coated pits [61].
4. Concluding remarks
Adenosine receptors are ubiquitous, but their effects are often cell-
speciﬁc. The localization of adenosine receptors in membrane
microdomains also appears to be cell- and receptor subtype-speciﬁc.
There appears to be signiﬁcant evidence that A1AR is localized in
ventricular cardiomyocyte caveolae under basal conditions, and there
are several reports that A1AR modulates signaling in these micro-
domains. In contrast, in renal epithelial cells and smooth muscle cells,
A1AR appears to translocate into caveolae after agonist stimulation, an
effect that could be related to A1AR internalization and desensitiza-
tion. Although it appears that cholesterol levels stabilize the apo-
A2aAR and modulate receptor signaling, evidence that this receptor
localizes in caveolae or lipid rafts is not conclusive and in some cases is
contradictory. There is little, if any, evidence to date that A2bAR and
A3AR are located in lipid rafts or caveolae.
Despite the evidence, or lack thereof, supporting the localization of
the four adenosine receptor subtypes in membrane microdomains,
much work remains to be conducted to understand the signiﬁcance of
these observations. For example, although there is little support for
A2bAR and A3AR in lipid rafts or caveolae, all four human receptorsappear to contain the caveolin bindingmotifs. Given the differences in
expression levels of adenosine receptor subtypes in various tissues,
their localization in lipid rafts/caveolae may also be cell-speciﬁc. Since
receptors may move in and out of these microdomains only under
certain conditions, their localization must be examined both in the
presence and absence of agonists and antagonists. Since ecto-5′-
nucleotidase appears to be localized in lipid rafts, the effects that
endogenous adenosine exerts on receptor localization must be
recognized. In order to better understand the physiological signiﬁ-
cance of adenosine receptor localization in lipid rafts/caveolae, the
expression of receptors and their signaling must be examined in both
these membrane microdomains as well as non-rafts and other
subcellular compartments. Investigators must also recognize the
limitations of the methods to isolate membrane microdomains as
well as the limitations of commercially available adenosine receptor
antibodies. Finally, given the signiﬁcant evidence that adenosine
receptorsmodulate cellular responses to stress, such as catecholamine
stimulation, oxidative stress, and ischemia–reperfusion, the role of
membranemicrodomains in modulating adenosine receptor signaling
must be examined under these conditions.References
[1] B.B. Fredholm, Adenosine receptors as drug targets, Exp. Cell Res. 316 (2010)
1284–1288.
[2] M.L. Trincavelli, S. Daniele, C. Martini, Adenosine receptors: what we know and
what we are learning, Curr. Top. Med. Chem. 10 (2010) 860–877.
[3] G. Schulte, B.B. Fredholm, Signalling from adenosine receptors to mitogen-
activated protein kinases, Cell. Signal. 15 (2003) 813–827.
[4] J.N. Peart, J.P. Headrick, Adenosinergic cardioprotection: multiple receptors,
multiple pathways, Pharmacol. Ther. 114 (2007) 208–221.
[5] T. Trost, K. Stock, Effects of adenosine derivatives on cAMP accumulation and
lipolysis in rat adipocytes and on adenylate cyclase in adipocyte plasma
membranes, Naunyn-Schmiedeberg's Arch. Pharmacol. 299 (1977) 33–40.
[6] M.F. Ethier, J.M. Madison, Adenosine A1 receptors mediate mobilization of
calcium in human bronchial smooth muscle cells, Am. J. Respir. Cell Mol. Biol. 35
(2006) 496–502.
[7] P. Gerwins, B.B. Fredholm, Stimulation of adenosine A1 receptors and bradykinin
receptors, which act via different G proteins, synergistically raises inositol 1, 4, 5-
trisphosphate and intracellular free calcium in DDT1 MF-2 smooth muscle cells,
Proc. Natl Acad. Sci. USA 89 (1992) 7330–7334.
[8] R.A. Fenton, E.D. Moore, F.S. Fay, J.G. Dobson Jr., Adenosine reduces the Ca2+
transients of isoproterenol-stimulated rat ventricular myocytes, Am. J. Physiol.
261 (1991) C1107–C1114.
[9] P. Narayan, R.M. Mentzer Jr., R.D. Lasley, Phosphatase inhibitor cantharidin blocks
adenosine A(1) receptor anti-adrenergic effect in rat cardiac myocytes, Am. J.
Physiol. Heart Circ. Physiol. 278 (2000) H1–H7.
[10] S. Dasgupta, S. Ferré, B. Kull, P. Hedlund, V. Finnman, S. Ahlberg, E. Arenas, B.B.
Fredholm, K. Fuxe, Adenosine A2A receptors modulate the binding characteristics
of dopamine D2 receptors in stably cotransfected ﬁbroblast cells, Eur. J.
Pharmacol. 316 (1996) 325–331.
[11] S. Ginés, J. Hillion, M. Torvinen, S. Le Crom, V. Casado, E.I. Canela, S. Rondin, J.Y.
Lew, S. Watson, M. Zoli, L. Agnati, P. Vernier, C. Lluis, S. Ferré, K. Fuxe, R. Franco,
Dopamine D1 and adenosine A1 receptors assemble into functionally interacting
heteromeric complexes, Proc. Natl Acad. Sci. USA 97 (2000) 8606–8611.
[12] M. Canals, D. Marcellino, F. Fanelli, F. Ciruela, P. de Benedetti, S.R. Goldberg, K.
Neve, K. Fuxe, L.F. Agnati, A.S. Woods, S. Ferré, C. Lluis, M. Bouvier, R. Franco,
Adenosine A2A-dopamine D2 receptor–receptor heteromerization: qualitative
and quantitative assessment by ﬂuorescence and bioluminescence energy
transfer, J. Biol. Chem. 278 (2003) 46741–46749.
[13] F. Ciruela, V. Casadó, R.J. Rodrigues, R. Luján, J. Burgueño, M. Canals, J. Borycz, N.
Rebola, S.R. Goldberg, J. Mallol, A. Cortés, E.I. Canela, J.F. López-Giménez, G.
Milligan, C. Lluis, R.A. Cunha, S. Ferré, R. Franco, Presynaptic control of striatal
glutamatergic neurotransmission by adenosine A1-A2A receptor heteromers, J.
Neurosci. 26 (2006) 2080–2087.
[14] R.G.W. Anderson, Caveolae: where incoming and outgoing messengers meet,
Proc. Natl Acad. Sci. USA 90 (1993) 10909–10913.
[15] G. Ferruccio, B. Razani, M.P. Lisanti, Emerging themes in lipid rafts and caveolae,
Cell 106 (2001) 403–411.
[16] L.D. Zajchowski, S.M. Robbins, Lipid rafts and little caves. Compartmentalized
signalling in membrane microdomains, Eur. J. Biochem. 269 (2002) 737–752.
[17] K. Jacobson, O.G. Mouritsen, R.G. Anderson, Lipid rafts: at a crossroad between cell
biology and physics, Nat. Cell Biol. 9 (2007) 7–14.
[18] C.M. Thomas, E.J. Smart, Caveolae structure and function, J. Cell. Mol. Med. 12
(2008) 796–809.
[19] K.S. Song, P.E. Scherer, Z.L. Tang, T. Okamoto, S. Li, M. Chafel, C. Chu, D.S. Kohtz, M.
P. Lisanti, Expression of caveolin-3 in skeletal, cardiac, and smooth muscle cells:
caveolin-3 is a component of the sarcolemma and co-fractionates with dystrophin
and dystrophin-associated glycoproteins, J. Biol. Chem. 271 (1996) 15160–15165.
1289R.D. Lasley / Biochimica et Biophysica Acta 1808 (2011) 1284–1289[20] K.S. Song, S. Li, T. Okamoto, L.A. Quilliam, M. Sargiacomo, M.P. Lisanti, Co-
puriﬁcation and direct interaction of Ras with caveolin, an integral membrane
protein of caveolae microdomains. Detergent-free puriﬁcation of caveolae
microdomains, J. Biol. Chem. 271 (1996) 9690–9697.
[21] J. Couet, S. Li, T. Okamoto, T. Ikezu, M.P. Lisanti, Identiﬁcation of peptide and
protein ligands for the caveolin-scaffolding domain: implications for the
interaction of caveolin with caveolae-associated proteins, J. Biol. Chem. 272
(1997) 6525–6533.
[22] Y. Toya, C. Schwencke, J. Couet, M.P. Lisanti, Y. Ishikawa, Inhibition of adenylyl
cyclase by caveolin peptides, Endocrinology 139 (1998) 2025–2031.
[23] T. Okamoto, A. Schlegel, P.E. Scherer, M.P. Lisanti, Caveolins, a family of scaffolding
proteins for organizing “preassembled signaling complexes” at the plasma
membrane, J. Biol. Chem. 273 (1998) 5419–5422.
[24] J.A. Engelman, C. Chu, A. Lin, H. Jo, T. Ikezu, T. Okamoto, D.S. Kohtz, M.P. Lisanti,
Caveolin-mediated regulation of signaling along the p42/p44 MAP kinase cascade
in vivo: a role for the caveolin-scaffolding domain, FEBS Lett. 428 (1998) 205–211.
[25] P.W. Shaul, R.G. Anderson, Role of plasmalemmal caveolae in signal transduction,
Am. J. Physiol. 275 (1998) L843–L851.
[26] R.S. Ostrom, P.A. Insel, The evolving role of lipid rafts and caveolae in G protein-
coupled receptor signaling: implications for molecular pharmacology, Br. J.
Pharmacol. 143 (2004) 235–245.
[27] A. Becher, R.A. McIlhinney, Consequences of lipid raft association on G-protein-
coupled receptor function, Biochem. Soc. Symp. 72 (2005) 151–164.
[28] Y.D. Paila, A. Chattopadhyay, Membrane cholesterol in the function and
organization of G-protein coupled receptors, Subcell. Biochem. 51 (2010)
439–466.
[29] E.J. Smart, Y.S. Ying, C. Mineo, R.G. Anderson, A detergent-free method for
purifying caveolae membrane from tissue culture cells, Proc. Natl Acad. Sci. USA
92 (1995) 10104–10108.
[30] C. Andersson-Forsman, L.E. Gustafsson, Cytochemical localization of 5′-nucleo-
tidase in the enteric ganglia and in smooth muscle cells of the guinea-pig, J.
Neurocytol. 14 (1985) 551–562.
[31] A. Kittel, E. Bacsy, Ecto-ATPases and 5′-nucleotidases in the caveolae of smooth
muscle. Enzyme-histochemical evidence may indicate a role for caveolae in
neurotransmission, Cell Biol. Int. 18 (1994) 875–879.
[32] G.R. Strohmeier, W.I. Lencer, T.W. Patapoff, L.F. Thompson, S.L. Carlson, S.J. Moe, D.
K. Carnes, R.J. Mrsny, J.L. Madara, Surface expression, polarization, and functional
signiﬁcance of CD73 in human intestinal epithelia, J. Clin. Invest. 99 (1997)
2588–2601.
[33] P. Abedinpour, B. Jergil, Isolation of a caveolae-enriched fraction from rat lung by
afﬁnity partitioning and sucrose gradient centrifugation, Anal. Biochem. 313
(2003) 1–8.
[34] S. Duﬂot, M. Calvo, F.J. Casado, C. Enrich, M. Pastor-Anglada, Concentrative
nucleoside transporter (rCNT1) is targeted to the apical membrane through the
hepatic transcytotic pathway, Exp. Cell Res. 281 (2002) 77–85.
[35] E. Errasti-Murugarren, M. Molina-Arcas, F.J. Casado, M. Pastor-Anglada, The
human concentrative nucleoside transporter-3 C602R variant shows impaired
sorting to lipid rafts and altered speciﬁcity for nucleoside-derived drugs, Mol.
Pharmacol. 78 (2010) 157–165.
[36] S. Mundell, E. Kelly, Adenosine receptor desensitization and trafﬁcking, Biochim.
Biophys. Acta. In press [Epub ahead of print].
[37] R.D. Lasley, P. Narayan, A. Uittenbogaard, E.J. Smart, Activated cardiac adenosine
A1 receptors translocate out of caveolae, J. Biol. Chem. 275 (2000) 4417–4421.
[38] A. Cavalli, M. Eghbali, T.Y. Minosyan, E. Stefani, K.D. Philipson, Localization of
sarcolemmal proteins to lipid rafts in the myocardium, Cell Calcium 42 (2007)
313–322.
[39] V. Garg, J. Jiao, K. Hu, Regulation of ATP-sensitive K+ channels by caveolin
enriched microdomains in cardiac myocytes, Cardiovasc. Res. 82 (2009) 51–58.
[40] K.S. Murthy, G.M. Makhlouf, Heterologous desensitization mediated by G protein-
speciﬁc binding to caveolin, J. Biol. Chem. 275 (2000) 30211–30219.
[41] P.A. Insel, B.P. Head, R.S. Ostrom, H.H. Patel, J.S. Swaney, C.M. Tang, D.M. Roth,
Caveolae and lipid rafts: G protein-coupled receptor signaling microdomains in
cardiac myocytes, Ann. N. Y. Acad. Sci. 1047 (2005) 166–172.
[42] R.P. Xiao, W. Zhu, M. Zheng, K. Chakir, R. Bond, E.G. Lakatta, H. Cheng, Subtype-
speciﬁc beta-adrenoceptor signaling pathways in the heart and their potential
clinical implications, Trends Pharmacol. Sci. 25 (2004) 358–365.[43] C. Ballard-Croft, A.C. Locklar, B.J. Keith, R.M. Mentzer Jr., R.D. Lasley, Oxidative
stress and adenosine A1 receptor activation differentially modulate subcellular
cardiomyocyte MAPKs, Am. J. Physiol. Heart Circ. Physiol. 294 (2008) H263–H271.
[44] Z. Yang, W. Sun, K. Hu, Adenosine A(1) receptors selectively target protein kinase
C isoforms to the caveolin-rich plasma membrane in cardiac myocytes, Biochim.
Biophys. Acta 1793 (2009) 1868–1875.
[45] H. Funakoshi, T.O. Chan, J.C. Good, J.R. Libonati, J. Piuhola, X. Chen, S.M.
MacDonnell, L.L. Lee, D.E. Herrmann, J. Zhang, J. Martini, T.M. Palmer, A. Sanbe,
J. Robbins, S.R. Houser, W.J. Koch, A.M. Feldman, Regulated overexpression of the
A1-adenosine receptor inmice results in adverse but reversible changes in cardiac
morphology and function, Circulation 114 (2006) 2240–2250.
[46] S.E. Woodman, D.S. Park, A.W. Cohen, M.W. Cheung, M. Chandra, J. Shirani, B.
Tang, L.A. Jelicks, R.N. Kitsis, G.J. Christ, S.M. Factor, H.B. Tanowitz, M.P. Lisanti,
Caveolin-3 knock-out mice develop a progressive cardiomyopathy and show
hyperactivation of the p42/44 MAPK cascade, J. Biol. Chem. 277 (2002)
38988–38997.
[47] E. Cheskis, P.H. Chung, B.R. DeGeorge, E.W. Feldman, H. Funakoshi, W. Jackson, J.-F.
Jasmin, W.J. Koch, M.P. Lisanti, X.-L. Ma, V.D. Myers, J. Song, J. Wagner, Y. Wang, D.
Whitaker-Menezes, R.V. Yelamarty, J. Zhang, J.Y. Cheung, T.O. Chan, A.M. Feldman,
Over-expression of the A1-adenosine receptor alters cardiac function by
inhibiting production of caveolin-3, Circulation 120 (2009) S874 (Abstract).
[48] S. Ginés, F. Ciruela, J. Burgueño, V. Casadó, E.I. Canela, J. Mallol, C. Lluís, R. Franco,
Involvement of caveolin in ligand-induced recruitment and internalization of A
(1) adenosine receptor and adenosine deaminase in an epithelial cell line, Mol.
Pharmacol. 59 (2001) 1314–1323.
[49] M. Escriche, J. Burgueño, F. Ciruela, E. Canela, J. Mallol, C. Enrich, C. Lluís, R. Franco,
Ligand-induced caveolae-mediated internalization of A1 adenosine receptors:
morphological evidence of endosomal sorting and receptor recycling, Exp. Cell
Res. 285 (2003) 72–90.
[50] F. Ciruela, C. Saura, E. Canela, J. Mallol, C. Lluís, R. Franco, Ligand-induced
phosphorylation, clustering, and desensitization of A1 adenosine receptors, Mol.
Pharmacol. 52 (1997) 788–797.
[51] E.C. Klaasse, A.P. Ijzerman, W.J. de Grip, M.W. Beukers, Internalization and
desensitization of adenosine receptors, Purinergic Signal. 4 (2008) 21–37.
[52] J. Mojsilovic-Petrovic, G.B. Jeong, A. Crocker, A. Arneja, S. David, D.S. Russell, R.G.
Kalb, Protecting motor neurons from toxic insult by antagonism of adenosine A2a
and Trk receptors, J. Neurosci. 26 (2006) 9250–9263.
[53] N. Assaife-Lopes, V.C. Sousa, D.B. Pereira, J.A. Ribeiro, M.V. Chao, A.M. Sebastião,
Activation of adenosine A2A receptors induces TrkB translocation and increases
BDNF-mediated phospho-TrkB localization in lipid rafts: implications for
neuromodulation, J. Neurosci. 30 (2010) 8468–8480.
[54] K. Kamata, S. Manno, M. Ozaki, Y. Takakuwa, Functional evidence for presence of
lipid rafts in erythrocyte membranes: Gsalpha in rafts is essential for signal
transduction, Am. J. Hematol. 83 (2008) 371–375.
[55] R.S. Lam, D. Nahirney, M. Duszyk, Cholesterol-dependent regulation of adenosine
A(2A) receptor-mediated anion secretion in colon epithelial cells, Exp. Cell Res.
315 (2009) 3028–3035.
[56] C. Charalambous, I. Gsandtner, S. Keuerleber, L. Milan-Lobo, O. Kudlacek, M.
Freissmuth, J. Zezula, Restricted collision coupling of the A2A receptor revisited:
evidence for physical separation of two signaling cascades, J. Biol. Chem. 283
(2008) 9276–9288.
[57] E. Lyman, C. Higgs, B. Kim, D. Lupyan, J.C. Shelley, R. Farid, G.A. Voth, A role for a
speciﬁc cholesterol interaction in stabilizing the Apo conﬁguration of the human
A(2A) adenosine receptor, Structure 17 (2009) 1660–1668.
[58] S.V. Sitaraman, L. Wang, M. Wong, M. Bruewer, M. Hobert, C.H. Yun, D. Merlin, J.L.
Madara, The adenosine 2b receptor is recruited to the plasma membrane and
associates with E3KARP and ezrin upon agonist stimulation, J. Biol. Chem. 277
(2002) 33188–33195.
[59] S.J. Mundell, A.L. Matharu, E. Kelly, J.L. Benovic, Arrestin isoforms dictate
differential kinetics of A2B adenosine receptor trafﬁcking, Biochemistry 39
(2000) 12828–12836.
[60] Y. Cordeaux, S.J. Briddon, S.P. Alexander, B. Kellam, S.J. Hill, Agonist-occupied A3
adenosine receptors exist within heterogeneous complexes in membrane
microdomains of individual living cells, FASEB J. 22 (2008) 850–860.
[61] A. Marchese, M. Paing, B. Temple, J. Trejo, G protein-coupled receptor sorting to
endosomes and lysosomes, Annu. Rev. Pharmacol. Toxicol. 48 (2008) 601–629.
